DEF 14A: Zynex, Inc. Announces Details for 2024 Annual Stockholders Meeting

Zynex, Inc. will hold its 2024 Annual Meeting of Stockholders on May 16, 2024, to elect directors and ratify the selection of its independent public accountant.

Summary

• Zynex, Inc. is holding its Annual Meeting of Stockholders on May 16, 2024, at its corporate headquarters in Englewood, Colorado.
• The meeting will include the election of four directors to serve until the 2025 Annual Meeting, ratification of Marcum LLP as the independent public accountant for the fiscal year ending December 31, 2024, and consideration of other business.
• Stockholders of record as of March 19, 2024, are entitled to vote.
• The Board of Directors recommends voting for the election of all director nominees and for the ratification of Marcum LLP as the independent registered public accounting firm.
• Proxy materials are primarily furnished via the Internet, with instructions provided to stockholders on how to access the materials and vote online.
• The company's Board of Directors consists of four members: Thomas Sandgaard, Barry D. Michaels, Michael Cress, and Joshua R. Disbrow.
• The company's named executive officers are Thomas Sandgaard (President, CEO, and Chairman), Daniel Moorhead (Chief Financial Officer), and Anna Lucsok (Chief Operating Officer).

Sentiment

Score: 6

Explanation: The document is primarily informational and procedural, with a neutral tone. While it includes some negative financial results, the overall sentiment is balanced.

Positives

• The company is committed to strong financial and operational performance while maintaining an excellent corporate governance environment.
• Zynex has been a leader in promoting women and minorities into leadership positions, and continues to cultivate a culture of inclusiveness and opportunity for all.
• The company offers a 401(k) plan to eligible employees.
• The company reimburses directors for reasonable out-of-pocket expenses incurred to attend Board and Committee meetings.

Negatives

• The company's total shareholder return decreased by 11% during the three-year period ended December 31, 2023.
• Net income decreased by 42.9% compared to the prior year, to $9.7 million in 2023 from $17.0 million in 2022.
• The company does not have a woman or a person representing a minority group on the Zynex board today.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Related party transactions have the potential to create actual or perceived conflicts of interest.
• The company's future performance is dependent on its ability to attract, motivate, and retain key executives.

Future Outlook

The company's future performance is dependent on its ability to attract, motivate, and retain key executives and on the success of its business strategies.

Industry Context

The document provides insight into the corporate governance practices, executive compensation, and board composition of a medical device company, which is relevant for understanding industry standards and best practices.

Comparison to Industry Standards

• The document references a comparator group of 16 publicly traded medical device and technology companies used for benchmarking executive compensation.
• The companies included in the comparator group were Accuray, Inc., AxoGen, Inc., Mesa Laboratories, Inc., Alphatec Holdings, Inc., Butterfly Network, Nevro Corporation, Apyx Medical Corp., Cerus Corp., Surmodics, Inc., Atrivion, Inc., Cutera, Inc., Tactile Systems Tech, AtriCure, Inc., Inogen, Inc., Atrion Corp., and IRadimed Corp.
• The document provides detailed information on director compensation, which can be compared to industry benchmarks for board compensation in similar-sized companies.

Stakeholder Impact

• The election of directors and ratification of the independent auditor will impact the company's governance and financial oversight.
• Executive compensation decisions will impact the motivation and retention of key personnel.
• The company's financial performance will impact shareholder value.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold its Annual Meeting of Stockholders on May 16, 2024.
• The company will file a current report on Form 8-K with the SEC to report the results of the Annual Meeting.

Key Dates

Keywords

proxy statement, annual meeting, directors, Marcum LLP, executive compensation, corporate governance, stockholders, Zynex